RCS - Creo Medical Group - CTO wins Technology Innovator of the Year Award

Creo MedicalAnnouncement

05/04/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220405:nRSE2295Ha&default-theme=true

RNS Number : 2295H  Creo Medical Group PLC  05 April 2022

REACH

Creo Medical Group plc

("Creo" the "Company" or the "Group")

 

Creo CTO & Founder wins inaugural Technology Innovator of the Year Award
at European Microwave Week

 

Chris Hancock wins $25,000 prize for first advanced energy multimodality
instrument designed for flexible endoscopy using combined bipolar RF and
microwave energy for advanced endoscopic procedures

 

Creo Medical Group plc (AIM: CREO), a medical device company focused on the
emerging field of surgical endoscopy, announces that its Chief Technology
Officer (CTO) and Founder, Chris Hancock, has won an inaugural Technology
Innovator of the Year Award at European Microwave Week.

 

The ceremony, sponsored by Junkosha, the pioneers of sophisticated
fluoropolymer application technologies across Interventional Medical and
Microwave and Millimeter Wave sectors, took place yesterday in London, UK, and
saw Chairperson of the Awards, Joe Rowan, present Chris with the Award and the
$25,000 prize.

 

Junkosha launched its Technology Innovator of the Year Award in March 2021 as
part of a celebration of milestones including its new corporate image and
website. The Award was designed to recognise the innovative work of an
individual or team working in the delivery of products used within
Interventional Medical procedures or Microwave/Millimeter Wave technologies.
Its aim was to highlight the achievements of pioneers in advanced technology
together with their contributions to society. Chris Hancock and Creo Medical
were selected by a distinguished panel of judges following presentations
completed by a shortlist of five candidates throughout February.

Chris Hancock is the founder and Chief Technology Officer of Creo Medical,
with over 20 years' experience in medical device development including four
years at Gyrus Group plc in his role as Senior Engineer. Chris holds a
personal Chair in the Medical Microwave Systems Research Group at Bangor
University and is a Fellow of the Institute of Physics, a Chartered Physicist,
a Fellow of the Institute of Engineering and Technology, a Chartered Engineer
and a Senior Member of the IEEE.

Joe Rowan, Chairperson for the Award, and Junkosha's President and CEO of USA
and Europe, explained: "We are very excited and proud to present Creo Medical
and Chris Hancock as our first Technology Innovator of the Year Award winner.
Chris' breakthrough technology holds the potential to transform the point of
treatments for a range of cancers. Overall, Chris' achievement is one we can
use as a yardstick to measure others in future years."

Mamoru Sogo, President and CEO of Junkosha Inc, said: "We believe that
enabling innovators, like Creo Medical, is central to the philosophy behind
the Junkosha brand as we continually look to advance the next generation of
technology for a better future. As part of the plans to raise awareness of our
new brand internationally, the Awards program delivers a tangible commitment
to our values. We congratulate Chris Hancock and Creo Medical on their Award
and look forward to observing their continued success well into the future."

Chris Hancock, Chief Technology Officer of Creo, commented: "I was delighted
to be nominated for this accolade, even more to win it and have the work we
are doing at Creo Medical recognised in this way. It is a real honour.

"Like most innovations - our products and the technology that powers them are
all products of an idea. From the beginning in 2001 our idea has always been
about harnessing advances in technology, together with creative and innovative
thinking, to help patients and to offer a better alternative for treating
cancer as well as other indications. I have been fortunate enough to see that
belief materialise into something that is transforming lives every day, and
which has the real potential to move the needle in how all manner of surgical
procedures are conducted.

"I look forward to ensuring that this $25k prize is used to empower and
encourage others with an idea or a passion to see it reach its potential. As
we've said many times at Creo - anything is possible with the right approach."

 

For more information about our Technology Innovation of the Year Awards, click
here: https://www.junkosha.com/en/news/54
(https://www.junkosha.com/en/news/54) .

 

Enquiries:

 

 Creo Medical Group plc                              www.creomedical.com (http://www.creomedical.com)
 Richard Rees (CFO)                                  +44 (0)1291 606 005

 Cenkos Securities plc                               +44 (0)20 7397 8900
 Stephen Keys / Camilla Hume (NOMAD)
 Michael Johnson / Russell Kerr (Sales)

 Numis Securities Limited (Joint Broker)             +44 (0)20 7260 1000

 Freddie Barnfield / James Black / Duncan Monteith

 Walbrook PR Ltd                                     Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com
 Paul McManus / Sam Allen /                          Mob: +44 (0)7980 541 893 / +44 (0)7502 558 258 / +44 (0)7867 984 082

 Phillip Marriage

 

 

About Creo Medical

 

Creo Medical is a medical device company focused on the development and
commercialisation of minimally invasive electrosurgical devices, bringing
advanced energy to endoscopy.

 

The Company's vision is to improve patient outcomes through the development
and commercialisation of a suite of electrosurgical medical devices, each
enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA
powered by Kamaptive full-spectrum adaptive technology to optimise surgical
capability and patient outcomes. Kamaptive is a seamless, intuitive
integration of multi-modal energy sources, optimised to dynamically adapt to
patient tissue during procedures such as resection, dissection, coagulation
and ablation of tissue. Kamaptive technology provides clinicians with
increased flexibility, precision and controlled surgical solutions. CROMA
currently delivers bipolar radiofrequency ("RF") energy for precise localised
cutting and focused high frequency microwave ("MW") energy for controlled
coagulation and ablation via a single accessory port. This technology,
combined with the Group's range of patented electrosurgical devices, is
designed to provide clinicians with flexible, accurate and controlled clinical
solutions. The Directors believe the Company's technology can impact the
landscape of surgery and endoscopy by providing a safer, less-invasive and
more cost-efficient option for procedures.

 

For more information, please refer to the website www.creomedical.com
(http://www.creomedical.com)

 

About Junkosha

Junkosha are pioneers of sophisticated fluoropolymer application technologies
across medical device and microwave interconnect sectors. With three
operations in Japan, including its headquarters as well as sites in the US, UK
and China, it is one of the best kept advanced technology secrets outside of
Japan. The company provides tube and fitting products, including generic resin
tubes, fluoropolymer tubes, high-barrier tubes, flexible multi-layered tubes,
industrial hoses, degassing modules, heat-shrinkable tubes, and the market
leading peelable heat shrink tubes. It also provides wire and cable products,
including microwave interconnects, robot cables, high data rate cables, camera
link cable assemblies, ultrafine coaxial cables and assemblies, cables for
clean environments, and general wires and cables.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRABCGDSRSGDGDS